Sign Up Today and Learn More About Intrinsic Therapeutics Stock
Invest in or calculate the value of your shares in Intrinsic Therapeutics or other pre-IPO companies through EquityZen's platform.
Intrinsic Therapeutics Stock (INTP)
Develops therapies to treat disc herniations in the spine for discectomy patients
About Intrinsic Therapeutics Stock
Founded
2000
Headquarters
Woburn, MA, US
Total Funding
219M
Industries
Manufacturing, Health Care
Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.
Intrinsic Therapeutics Press Mentions
Stay in the know about the latest news on Intrinsic Therapeutics
Dave Amerson and Tyler Binney Add Their Experience Commercializing Disruptive Technologies to Intrinsic ...
prnewswire • Apr 10, 2024
Navigating the Landscape of Herniated Discs: A Rare Case of ...
cureus • Jan 19, 2024
NYU Langone Performs First U.S. Procedure with Newly Approved Device to Reduce Herniated Disc Recurrence
prnewswire • Jun 14, 2019
Anaconda Biomed Expands Leadership Team with Two New Senior Hires
businesswire • Mar 01, 2019
Intrinsic Therapeutics wins PMA for Barricaid spinal implant despite safety concerns
massdevice • Feb 13, 2019
Intrinsic Therapeutics Management
Leadership team at Intrinsic Therapeutics
Vice President, Global Sales
Remco Maljers
CFO
David Neafus
Join now and verify your accreditation status to gain access to:
- Intrinsic Therapeutics current valuation
- Intrinsic Therapeutics stock price
- Available deals in Intrinsic Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Intrinsic Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Intrinsic Therapeutics through EquityZen funds. These investments are made available by existing Intrinsic Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Intrinsic Therapeutics stock?
Shareholders can sell their Intrinsic Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
